Tags : Novo Nordisk

Novo Nordisk, Genentech and Sanofi to cut off jobs in

     Shots: Novo Nordisk lay off nearly 250 employees in US due to slow revenue growth, and they will hire undetermined numbers of new employees in new positions Genentech to cutback 223 job in their South San Francisco HQ due decline in sales due to biosimilar version of MabThera/Rituxan and the sales of Herceptin and […]Read More

Novo Nordisk’s Tresiba Receives Health Canada Approval for Type 1

Shots: Novo Nordisk’s Tresiba has received an approval for indication expansion by Health Canada for the treatment of pediatric patients (>2 years of age) with Type 1 diabetes The expanded indication follows its last approval in Canada on Aug 2017 for the treatment of adults with Type 1 and Type 2 diabetes Tresiba (insulin degludec injection) is […]Read More

Novo Nordisk Launches a 24/7 Online Chatbot Specifically for People

Shots: Novo Nordisk launched Sophia Chatbot, available on Cornerstones4Care as “Ask Sophia “tab, directly answers questions and addresses concerns/forwards/ redirects when it doesn’t know the answer The launch is in response to the diabetic patients gathering information late at night when the treatment team is unavailable Sophia is built on grounds of artificial intelligence and […]Read More

Novo Nordisk launches Ozempic DTC campaign for type 2 Diabetes

Shots: The intense market competition leads Novo to focus direct-to-consumer campaign for Ozempic, a once weekly Injectable Type 2 diabetes First sales through total diabetic care fell 5% y-o-y with 8% decline in profit GLP-1 has shown bright spot in Novo Nordisk’s portfolio, with increase of sale 20% in US and 12% outside US Click […]Read More